Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2813—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the present invention relates to pharmaceutical compositions comprising (4- ⁇ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-pheny ⁇ -cyclohexyl)-acetic acid, or a pharmaceutically acceptable salt thereof, e.g. the sodium salt thereof, as the active ingredient in a suitable carrier.
• the present invention also relates to the processes for their preparation and to their use as medicaments.
• DGAT1-inhibitors including, at Example 5-1, the compound (4- ⁇ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl ⁇ -cyclohexyl)-acetic acid, having the structural formula (I):
• a condition or a disorder such as inflammatory conditions, obesity, diabetes and related metabolic disorders.
• parenteral administration is preferred to parenteral administration because it allows self-administration by patients whereas parenteral formulations have to be administered in most cases by a physician or paramedical personnel. It is also important that dosage units which are manufactured and given to a patient have a high degree of uniformity in the amount of drug substance among the individual dosage units. In addition, the formulation must have a good dissolution profile and an optimal in-vivo drug-release profile with minimal unit-to-unit variability.
• the compound of formula (I), or a pharmaceutically acceptable salt thereof, in particular the sodium salt thereof is a drug substance which is difficult to formulate due to its physicochemical properties. More particularly, the sodium salt of the compound of formula (I), depicted above as the compound of formula (II), is hygroscopic, poorly soluble and highly permeable, with a high moisture uptake at 95% relative humidity. It is also plate like, very fluffy, and sticky in nature. It also exhibits poor flow characteristics.
• Example 1 The formulations of Example 1, for instance, were very sensitive to process parameters. It was found that compression at different hardnesses led to very different dissolution profiles. It was thus necessary to reduce the tablet to tablet variability of the drug release of the formulation, as this would have a major impact on the in-vivo availability of the drug. It was also necessary to develop a formulation which would be more robust to process parameters, and which would avoid one of the major problems associated with the compound of formula (II), i.e. its stickiness.
• the invention thus provides a pharmaceutical composition of the compound of formula (I), or a pharmaceutically acceptable salt thereof, which exhibits one or more, e.g. 1, 2 or 3, of the following desirable characteristics;
• the formulations of the present invention are also achievable via a robust manufacturing process; which gives good flowability, compactability, and which minimizes sticking problems and capping of tabletting mixtures on the rotary press.
• the process and the formulations are amenable to scale-up, with a reproducible performance.
• the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising
• the pharmaceutical composition in accordance with the present invention is, as defined in claim 1 .
• the use of the specified excipients surprisingly overcomes the problems of formulating the compound of formula (I), or a pharmaceutically acceptable salt, in particular the sodium salt of formula (II), into a solid oral dosage form.
• the present invention provides a composition which shows good physical and chemical stability during storage, which has a good dissolution profile, which is not sensitive to manufacturing parameters, and in which the unit to unit variation in drug release is minimized.
• the present invention also provides a process which enables maximum drug load to be achieved and which is not sensitive to manufacturing parameters.
• compositions of the present invention contain one or more, e.g. 1, 2 or 3, surfactants which have lubricant properties.
• the surfactants to be employed in accordance in the present invention include, without limitation, sodium lauryl sulfate (SLS), stearic acid, palmitic acid, myristic acid, poloxamers and polyethylene glycols such as PEG 4000-8000, Tween series of surfactants, Brij series of surfactants (i.e., Brij 80), Triton X-100, and combinations thereof, preferably Sodium lauryl sulfate (SLS).
• SLS sodium lauryl sulfate
• stearic acid palmitic acid
• myristic acid poloxamers
• polyethylene glycols such as PEG 4000-8000
• Tween series of surfactants i.e., Brij 80
• Triton X-100 Triton X-100
• SLS Sodium lauryl sulfate
• the surfactant or combination of surfactants may be employed in an amount ranging from about 0.1% to about 5%, preferably from about 0.5% to about 3%, e.g. 2%, by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
• compositions of the present invention in addition contain one or more, e.g. 1, 2 or 3, binders with lubricant properties.
• the dry binders to be employed in accordance in the present invention include, without limitation, polyethylene glycols (PEG), e.g., PEG 4000; pregelatinized starch; starch; chitosan; guar gum, microcrystalline cellulose; methyl cellulose; calcium carboxymethylcellulose; sodium carboxymethylcellulose, alginic acid and/or its sodium salt; hydroxypropylmethyl cellulose or hydroxypropyl cellulose, both preferably of medium to high viscosity, e.g., viscosity grades 3 or 6 cps, e.g. low substituted hydroxypropyl cellulose (L-HPC LH-21); and combinations thereof.
• PEG polyethylene glycols
• PEG 4000 pregelatinized starch
• starch chitosan
• guar gum microcrystalline cellulose
• methyl cellulose calcium carboxymethylcellulose
• sodium carboxymethylcellulose alginic acid and/or its sodium salt
• a most preferred binder is low substituted hydroxypropyl cellulose (L-HPC LH-21).
• the dry binder or combination of dry binders may be employed in an amount ranging from about 2% to about 20%, preferably from about 5% to about 15%, e.g. about 10% by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
• the fillers to be employed in accordance in the present invention include, without limitation, microcrystalline cellulose (e.g., cellulose MK GR and products available under the registered trade marks AVICEL, FILTRAK, HEWETEN or PHARMACEL, Vivapur, emcocel, tabulose), low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, Anhydrous Dicalcium Phosphate, Dicalcium Phosphate, lactose, Anhydrous Lactose, and combinations thereof.
• microcrystalline cellulose e.g., cellulose MK GR and products available under the registered trade marks AVICEL, FILTRAK, HEWETEN or PHARMACEL, Vivapur, emcocel, tabulose
• low-substituted hydroxypropyl cellulose e.g., cellulose MK GR and products available under the registered trade marks AVICEL, FILTRAK
• the filler is microcrystalline cellulose, Anhydrous Dicalcium Phosphate and Anhydrous Lactose, or a mixture thereof.
• Combination of fillers may be used such as combinations of microcrystalline cellulose and Anhydrous Dicalcium Phosphate, and combinations of microcrystalline cellulose and lactose.
• the filler or combination of fillers may be employed in an amount ranging from about 4% to about 85%, preferably from about 20% to about 85%, most preferably from about 50-80%, e.g., 50-65% or 70-80% by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
• fillers When combinations of fillers are used, they may be used in a ratio of from 1:1 to 1:5, preferably 1:2 ratio.
• the filler is a combination of microcrystalline cellulose and another filler, e.g. Anhydrous Dicalcium Phosphate, or lactose, wherein the ratio of the microcrystalline cellulose to lactose, or of microcrystalline cellulose to anhydrous dicalcium phosphate is 1:2.
• the disintegrants to be employed in the pharmaceutical compositions of the present invention can be extragranular or intragranular, or both.
• examples of disintegrants to be employed in accordance in the present invention include, without imitation, carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na) or crosscarmellose sodium, e.g. AC-Di-SOL, Sodium Starch Glycollate (SSG); alginic acid, sodium alginate and guar gum; preferably crosscarmellose sodium, e.g. AC-DI-SOL, cross-linked polyvinyl pyrrolidone (e.g. CROSPOVIDONE, POLYPLASDONE or KOLLIDON XL), Sodium Starch Glycollate (SSG).
• CMC-Ca carboxymethylcellulose calcium
• CMC-Na carboxymethylcellulose sodium
• crosscarmellose sodium e.g. AC-Di-SOL, Sodium Starch Glycollate (SSG)
• a most preferred disintegrant is Sodium Starch Glycollate (SSG).
• the disintegrant or combination of disintegrants may be employed in an amount ranging from about 0.5% to about 25%, preferably from about 1% to about 10%, most preferably from about 1% to about 6%, by weight of the tablet (prior to any optional film coating). In one embodiment, the disintegrant is present in an amount which is 2, 6 or 9% by weight of the tablet. These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
• Lubricants may provide advantages in the formulation of a pharmaceutical composition when the drug substance is poorly water soluble and a compaction process, such as a roller compaction process, is used with drug loads as high as 25% w/w.
• the pharmaceutical compositions of the present invention may in addition contain one or more, e.g. 1, 2 or 3, lubricants.
• the lubricants to be employed in accordance in the present invention include, without limitation, magnesium stearate, aluminum or calcium silicate, stearic acid, cutina, PEG 4000-8000, talc and combinations thereof, preferably Sodium Stearyl Fumarate or magnesium stearate, more preferably Sodium Stearyl Fumarate.
• the lubricant or lubricants may be employed in an amount ranging from about 0.1% to about 10%, preferably from about 0.5% to about 5%, e.g. 2-3%, by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
• the compound of formula (I), or a pharmaceutically acceptable salt may be employed in an amount ranging from about 0.1% to about 50%, preferably from about 0.5% to about 30%, most preferably from about 1-30%, by weight of the pharmaceutical compositions (prior to any optional film coating).
• the compound of formula (I) may be present in 2, 10, 15, 20, 25 and 30% by weight of the pharmaceutical compositions. These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
• the amount of each additive in a pharmaceutical oral fixed dose combination may vary within ranges conventional in the art.
• Suitable glidants include, without limitation, colloidal silicon dioxide (e.g., Aerosil 200), magnesium trisilicate, powdered cellulose, starch, talc and combinations thereof.
• a glidant or glidants in the layer containing component a) may be employed in an amount ranging from about 00.05% to about 5%, preferably from about 0.1% to about 1%, more preferably from about 0.25% to about 1%, e.g. 0.25 or 0.5%, by weight of the tablet (prior to any optional film coating). These percentages are based on the compound of the formula (I) and if a salt is used the percentages will be adapted accordingly.
• the invention provides a pharmaceutical composition, as described in claim 1 .
• a pharmaceutical composition, according to embodiment 1, wherein the surfactant with lubricant properties is selected from, sodium lauryl sulfate (SLS), stearic acid, palmitic acid, myristic acid, poloxamers and polyethylene glycols such as PEG 4000-8000, Tween series of surfactants.
• Brij series of surfactants i.e., Brij 80
• Triton X-100 and combinations thereof, preferably Sodium lauryl sulfate (SLS).
• PEG polyethylene glycols
• pregelatinized starch starch
• starch chitosan
• guar gum microcrystalline cellulose: methyl cellulose; calcium carboxymethylcellulose; sodium carboxymethylcellulose, alginic acid and
• a pharmaceutical composition according to any one of embodiments 1 to 3, wherein the filler is selected from microcrystalline cellulose (e.g., cellulose MK GR and products available under the registered trade marks AVICEL, FILTRAK, HEWETEN or PHARMACEL, Vivapur, emcocel, tabulose), low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, Anhydrous Dicalcium Phosphate, Dicalcium Phosphate, lactose, Anhydrous Lactose, and combinations thereof.
• microcrystalline cellulose e.g., cellulose MK GR and products available under the registered trade marks AVICEL, FILTRAK, HEWETEN or PHARMACEL, Vivapur, emcocel, tabulose
• low-substituted hydroxypropyl cellulose hydroxyethyl cellulose, hydroxypropyl methyl cellulose
• a pharmaceutical composition according to any one of embodiments 1 to 4, wherein the disintegrant is selected from carboxymethylcellulose calcium (CMC-Ca), carboxymethylcellulose sodium (CMC-Na) or crosscarmellose sodium, e.g. AC-DI-SOL, Sodium Starch Glycollate (SSG); alginic acid, sodium alginate and guar gum; preferably crosscarmellose sodium, e.g. AC-DI-SOL, cross-linked polyvinyl pyrrolidone (e.g. CROSPOVIDONE, POLYPLASDONE or KOLLIDON XL), Sodium Starch Glycollate (SSG).
• compositions provided herein may contain in addition, lubricants, glidants, colorants, and combinations thereof, as detailed above.
• the amounts of each of the excipients, and the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, are as described herein, and as described in the Examples.
• breaking force or “resistance to crushing” as used herein refers to the force required to cause a tablet to fail (i.e., break) in a specific plane.
• the hardness is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopoeias U.S. Pat. No. ⁇ 1217> and EP 2.9.8 and JP. If the tablet is too soft, it will not withstand handling during the subsequent processing, such as coating or packaging and shipping operations. Likewise, if the tablet is too hard, it may not disintegrate in the required period of time or meet the dissolution specification. A general principle for hardness testing is that the larger the tablet, the higher the hardness. It is thus a goal of the formulator to improve the compression/hardness profile so as to minimize the influence of hardness on disintegration time and dissolution, and to maximize the drug load.
• release refers to a process by which the pharmaceutical oral fixed dose combination is brought into contact with a fluid and the fluid transports the drug(s) outside the dosage form into the fluid that surrounds the dosage form.
• the combination of delivery rate and delivery duration exhibited by a given dosage form in a patient can be described as its in vivo release profile.
• the release/dissolution profiles of dosage forms may exhibit different rates and durations of release and may be continuous.
• Continuous release profiles include release profiles in which one or more, e.g. 1, 2 or 3, active ingredients are released continuously, either at a constant or variable rate.
• An adequate drug release profile for the pharmaceutical composition may be e.g. 80% within 45 minutes.
• disintegration refers to a process where the pharmaceutical oral fixed dose combination, typically by means of a fluid, falls apart into separate particles and is dispersed. Disintegration is achieved when the solid oral dosage form is in a state in which any residue of the solid oral dosage form, except fragments of insoluble coating or capsule shell, if present, remaining on the screen of the test apparatus is a soft mass having no palpably firm core in accordance with U.S. Pat. No. ⁇ 701>.
• the fluid for determining the disintegration property is water, such as tap water or deionized water.
• the disintegration time is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopoeias U.S. Pat. No. ⁇ 701> and EP 2.9.1 and JP.
• dissolution refers to a process by which a solid substance, here the active ingredients, is dispersed in molecular form in a medium.
• the dissolution rate of the active ingredients of the pharmaceutical oral fixed dose combination of the invention is defined by the amount of drug substance that goes in solution per unit time under standardized conditions of liquid/solid interface, temperature and solvent composition.
• the dissolution rate is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopoeias U.S. Pat. No. ⁇ 711> and EP 2.9.3 and JP.
• the test is for measuring the dissolution of the individual active ingredients is performed following pharmacopeia U.S. Pat. No.
• the dissolution medium is preferably a buffer, typically a phosphate buffer, especially one as described in the example “Dissolution Test”.
• the molarity of the buffer is preferably 0.1 M.
• An adequate dissolution profile for a slowly dissolving or poorly water soluble drug may mean for example, more than 80%, e.g. 85%, dissolution within 30, 45, or 60 minutes, see e.g. Guidance for industry: Dissolution Testing of immediate Release Solid Oral Dosage Forms , August 1997, p. 5.
• particulate refers to a state of matter which is characterized by the presence of discrete particles, pellets, beads or granules irrespective of their size, shape or morphology. When a plurality of particulates is present, these are referred to as multiparticulates.
• the particulates have an average size of lower than about 3 mm, preferably between about 1 ⁇ m to 3 mm.
• average particle size it is meant that at least 50% of the particulates have a particle size of less than about the given value, by weight.
• the particle size may be determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation.
• ⁇ ективное amount refers to the amount of the active ingredient or agent which halts or reduces the progress of the condition being treated or which otherwise completely or partly cures or acts palliatively on the condition.
• prophylactically effective amount refers to the amount of the active ingredient or agent prevents the onset of the disease, condition or disorder.
• warm-blooded animal or patient are used interchangeably herein and include, but are not limited to, humans, dogs, cats, horses, pigs, cows, monkeys, rabbits, mice and laboratory animals. In one embodiment, the mammals are humans.
• treatment means the management and care of a patient for the purpose of preventing, combating or delaying progression of the disease, condition or disorder, preferably for the purpose of combating the disease, condition or disorder, and in particular it also prophylactic treatment.
• prevention /“preventing” are to be understood as meaning the prophylactic administration of a drug, such as a combined preparation or pharmaceutical composition, to healthy patients to prevent the outbreak of the disease, condition or disorder.
• delay of progression /“delaying progression” are to be understood as meaning the administration of a drug, such as a combined preparation or pharmaceutical composition, to patients being in a pre-stage of the disease, condition or disorder.
• drug active substance
• active ingredient active agent
• the present invention overcomes the drawbacks associated with formulating the drug substance and provides a specific process for preparing a pharmaceutical composition comprising the compound of the formula (I), or a pharmaceutically acceptable salt thereof.
• the invention provides in another of its aspects a process of making a solid oral dosage form as hereinabove described.
• a solid oral dosage form may be produced by working up the final composition defined hereinabove in appropriate amounts, to form unit dosage forms.
• a process for preparing a pharmaceutical composition comprising the steps of mixing compound of formula (I), or a pharmaceutically acceptable salt thereof, with at least one pharmaceutically acceptable excipient to form a blend; compacting, such as roller compacting, said blend; optionally mixing with further pharmaceutically acceptable excipients, and optionally compressing the final blend into a solid oral dosage form.
• a further embodiment of the present invention is a process for the manufacture of a tablet according to the present invention.
• the pharmaceutical oral fixed compositions of the invention are tablets of low friability.
• the friability is not more than 0.8%.
• the friability is measured by standard methods known to the person skilled in the art, see the harmonized procedure set forth in the pharmacopoeias U.S. Pat. No. ⁇ 1216> and EP 2.9.7 and JP.
• the pharmaceutical oral fixed compositions of the invention are tablets of suitable hardness (e.g. an average hardness ranging from about 30 N to about 110 N). Such an average hardness is determined prior to the application of any film coating on the pharmaceutical oral fixed dose combinations.
• a preferred embodiment of this invention is directed to pharmaceutical oral compositions which are film-coated.
• suitable film coatings are known and commercially available or can be made according to known methods.
• the film coating material is a polymeric film coating material comprising materials such as hydroxypropylmethyl cellulose or polyvinyl alcohol, polyethylene glycol, lecithin, talc and colorant.
• a film coating material is applied in such an amount as to provide a film coating that ranges from about 1% to about 6% by weight of the film-coated tablet.
• a coating comprising polyvinyl alcohol and materials such as polyethylene glycol, talc, and colorants (such as Opadry AMB or Opadry 1185F) can be applied as a moisture barrier to provide additional moisture protection to prevent conversion of the active ingredient to other polymorphic forms.
• Sufficient moisture protection can also be achieved through various packaging, including but not limited to: heat-induction sealed HDPE bottles with or without desiccant, and blister packaging materials known in the industry to have low moisture vapor permeation rates (i.e. aluminum/aluminum, PVC/PCTFE (polyvinylchloridepolychlorotrifluoroethylene), ACLAR).
• the invention provides a process for the preparation of pharmaceutical oral compositions as described herein above.
• Such pharmaceutical oral fixed dose combination may be produced by working up components as defined herein above in the appropriate amounts, to form unit pharmaceutical oral fixed dose combinations.
• the pharmaceutical compositions are useful in treating or preventing a condition or disorder associated with DGAT1 activity.
• the conditions for which the instant invention is useful include, without limitation, a metabolic disorder such as obesity, diabetes, anorexia nervosa, bulimia, cachexia, syndrome X, insulin resistance, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, chlomicronemia, familial chylomicronemia, and nonalcoholic fatty liver disease: cardiovascular diseases, such as atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis, and vascular stenosis; neoplastic diseases, such as solid tumors, skin cancer, melanoma, lymphoma, and endothelial cancers, for example, breast cancer, lung cancer, color
• the present invention thus provides a method for treating or preventing a condition or disorder associated with DGAT1 activity, comprising administering to an animal, including a human patient, in need of such treatment a therapeutically effective amount of the pharmaceutical composition according to the present invention.
• the present invention likewise provides the use of a pharmaceutical composition according to the present invention for the manufacture of a medicament for treating or preventing a condition or disorder associated with DGAT1 activity.
• the present invention likewise provides a pharmaceutical composition according to the present invention for use in treating or preventing a condition or disorder associated with DGAT1 activity.
• the exact dose of the active agent and the particular formulation to be administered depend on a number of factors, e.g., the condition to be treated, the desired duration of the treatment and the rate of release of the active agent.
• the amount of the active agent required and the release rate thereof may be determined on the basis of known in vitro or in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect.
• the tablets of the Examples are tested for their dissolution in 900 ml of pH 6.8 phosphate buffer with paddles at 75 rpm.
• the assembly consists of the following: a covered vessel made of glass or other inert, transparent material; a motor, and a paddle formed from a blade and shaft as the stirring element.
• the vessel is partially immersed in a suitable water bath of any convenient size or placed in a heating jacket.
• the water bath or heating jacket permits holding the temperature inside the vessels at 37 ⁇ 0.5° during the test and keeping the bath fluid in constant, smooth motion.
• Apparatus that permits observation of the specimen and stirring element during the test is has the following dimensions and capacities: the height is 160 mm to 210 mm and its inside diameter is 98 mm to 106 mm.
• the shaft is positioned so that its axis is not more than 2 mm at any point from the vertical axis of the vessel and rotates smoothly without significant wobble.
• the vertical center line of the blade passes through the axis of the shaft so that the bottom of the blade is flush with the bottom of the shaft.
• the design of the paddle is as shown in U.S. Pat. No. ⁇ 711>, FIG. 2.
• the distance of 25 ⁇ 2 mm between the blade and the inside bottom of the vessel is maintained during the test.
• the metallic or suitably inert, rigid blade and shaft comprise a single entity.
• a suitable two-part detachable design may be used provided the assembly remains firmly engaged during the test.
• the paddle blade and shaft may be coated with a suitable inert coating.
• the dosage unit is allowed to sink to the bottom of the vessel before rotation of the blade is started.
• a small, loose piece of nonreactive material such as not more than a few turns of wire helix may be attached to dosage units that would otherwise float.
• Other validated sinker devices may be used.
• 1 L of a buffered aqueous solution, adjusted to pH 6.8 ⁇ 0.05 0.05 M Phosphate buffer solution obtained by dissolving 6.805 g of potassium dihydrogen phosphate and 0.896 g of sodium hydroxide in and diluting to 1000 ml with water, and adjusting the pH to 6.80 ⁇ 0.05 using 0.2M sodium hydroxide or 1M phosphoric acid; referred hereinafter as “Dissolution Medium”
• Dissolution Medium 0.05 M Phosphate buffer solution obtained by dissolving 6.805 g of potassium dihydrogen phosphate and 0.896 g of sodium hydroxide in and diluting to 1000 ml with water, and adjusting the pH to 6.80 ⁇ 0.05 using 0.2M sodium hydroxide or 1M phosphoric acid; referred hereinafter as “Dissolution Medium”
• a specimen (>1 ml) is withdrawn from a zone midway between the surface of the Dissolution Medium and the top of the rotating blade, not less than 1 cm from the vessel wall.
• NOTE the aliquots withdrawn for analysis are replaced with equal volumes of fresh Dissolution Mediums at 37) or, where it can be shown that replacement of the medium is not necessary, the volume change is corrected in the calculation.
• the vessel is kept covered for the duration of the test, and the temperature of the mixture under test at suitable times is verified].
• the specimen is filtered through a suitable filter, e.g. a 0.45 ⁇ m PVDF filter (Millipore) and the first mls (2 to 3 ml) of the filtrate are discarded.
• a suitable filter e.g. a 0.45 ⁇ m PVDF filter (Millipore) and the first mls (2 to 3 ml) of the filtrate are discarded.
• the analysis is performed by HPLC or UV detection.
• the test is repeated at least 6 times, with additional dosage form units.
• a Schleuniger 8M Hardness tester was used to perform tablet hardness testing. Tablets were positioned on the instrument stage. Each tablet was oriented in the lengthwise same position according to distinguishing marks (when applicable).
• trans-(4- ⁇ 4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl ⁇ -cyclohexyl)-acetic acid, sodium salt along with Microcrystalline Cellulose (partial), and Crospovidone (intragranular) are mixed in a low shear mixer.
• the mixed contents, along with remaining Microcrystalline Cellulose are passed through an oscillating mill equipped with a suitable screen.
• the screened contents are mixed in a low shear mixer for a suitable amount of time.
• Colloidal silicon dioxide, screened through an appropriate screen is mixed with the blend from earlier step and the contents are mixed for a suitable amount of time.
• Magnesium Stearate screened through a suitable screen size is added to the preblend and mixed for a suitable amount of time.
• the lubricated intragranular preblend is passed through a roller compaction system for densification at the optimized parameters for feed rate, roll speed and roll force.
• the ribbons from the process are collected and passed through an oscillating mill equipped with a suitable screen to get the desired milled material.
• the milled material is then mixed with extragranular prescreened Crospovidone and mixed in a low shear mixer for a suitable amount of time.
• prescreened Magnesium Stearate is added and mixed for a suitable amount of time.
• the final blend is then compressed to the desired tablet weight to achieve the optimized thickness, hardness and disintegration time.
• Uncoated Tablet Comprising a DGAT1 Inhibitor, (10 mg of Active Ingredient, Based on Free Acid of Compound 1)
• Example 1.A The Table below shows the dissolution of tablets of Example 1.A which are compressed at two different hardness i.e. 6 kN and 12 kN.
• the dissolution for the batches was performed using USP-2 Paddle/0.4% CTAB/pH 6.8 buffer/50 rpm.
• Example 1A (at two hardness levels) % compound of formulat (II) released (% w/w) at the following time points (in minutes) Compression 10 20 30 45 60 hardness min min min min min 6 kN 65 82 91 101 103 12 kN 48 77 82 86 89
• Microcrystalline cellulose (Avicel), surfactant (sodium lauryl sulfate), disintegrant (Internal), and glidant (Aerosil 200) (internal) are added to the therapeutic agent.
• the mixture is sieved and blended prior to lubrication.
• the lubricant (Internal) is then added to the bin blender and blended for an appropriate amount of time.
• the mixture is roller compacted using a roller compactor, and then milled.
• Disintegrant (External), and glidant (Aerosil 200) (External) are added to the mixture and bin blended. Thereafter, the obtained mixture is blended with lubricant (external excipient), sieved in a bin blender.
• the obtained final mixture is then compressed into a tablet weighing about 100 mg.
• the table below shows the effect of a surfactant with lubricant properties.
• the following Table shows two formulations, one with and the other without Sodium Lauryl Sulfate.
• Example 2A Example 2B Strength 25 mg 25 mg mg/tablet mg/tablet Materials Compound of formula (II) 26.28 26.28 Sodium Lauryl Sulfate — 2 Avicel PH 102 18.22 18.22 Anhydrous Lactose 36 36 Sodium Starch Glycollate 3 3 (Internal) L-HPC LH 21 10 10 Aerosil 200 (Internal) 0.25 0.25 Sodium Stearyl Fumarate 0.5 0.5 (internal) Sodium Starch Glycollate 3 3 (External) Aerosil 200 (External) 0.25 0.25 Sodium Stearyl Fumarate 0.5 0.5 (External) Total weight (mg) 100 100 Tablet properties Tooling 6 mm round 6 mm round Mean weight (mg) 99.4 100.5 Compression force (kN) 4.1 4.9 Mean hardness (N) 64.2 64.2 L-HPC LH 21: low substituted hydroxypropyl cellulose
• Example 2 (with and without surfactant) % compound released (% w/w) at the following time points (in minutes) Sample 10 20 30 45 60 Without 30 66 87 93 95 surfactant With 2% 50 84 92 94 94 surfactant
• the dissolution comparison clearly indicates the faster rate of dissolution at the initial two time points for the formulation with 2% w/w of SLS. Moreover, during the processing of the batch containing SLS, it was observed that the sticking tendency to the rolls of the compactor was also significantly reduced. Hence the advantages from the dissolution and processing standpoint made it crucial to include a surfactant with lubricant properties in the formulation.
• Example 3B The effect of a dry binder with disintegrant properties can be evaluated as follows.
• Example 3B the non-inclusion of L-HPC LH-21 was compensated by a similar amount of Avicel PH-102 in the external phase.
• Example 3A Example 3B Strength 25 mg 25 mg Mg/tablet Mg/tablet Materials Compound of formula (II) 26.28 26.28 Sodium Lauryl Sulfate 2 2 Avicel PH 102 (Internal) 16.72 16.72 Anhydrous Lactose 36 36 Sodium Starch Glycollate (Internal) 3 3 L-HPC LH 21 10 — Aerosil 200 (Internal) 0.25 0.25 Sodium Stearyl Fumarate (Internal) 1 1 Avicel PH 102 (External) — 10 Sodium Starch Glycollate (External) 3 3 Aerosil 200 (External) 0.25 0.25 Sodium Stearyl Fumarate (External) 1.5 1.5 Total weight (mg) 100 100 Tablet properties Tooling 6 mm standard round, 6 mm standard round, Mean weight (mg) 102.4 101.0 Compression force (kN) 8.4 8.1 Mean hardness (N) 89.0 89.2 % friability (500 rotations) 0.06 0.65 L
• a dry binder with lubricant properties is an essential component of the formulations of the present invention.
• Example 4A and 4B are given in the Table below.
• the therapeutic agent in these examples is the compound of formula (II).
• the table below shows the formulation for Examples 5A, 5B and 5C having 25 mg of therapeutic agent—the 25 mg refers to the amount of the compound of formula (I).
• Examples 5A, 5B and 5C provide possible embodiments of a tablet dosage form using various disintegrants.
• Microcrystalline cellulose (Avicel), sodium lauryl sulfate, disintegrant (Internal), and Aerosil 200 (Internal) are added to the therapeutic agent.
• the mixture is sieved and blended prior to lubrication.
• the Sodium Stearyl Fumarate (Internal) is then added to the bin blender and blended for an appropriate amount of time.
• the mixture is roller compacted using a roller compactor, and then milled.
• Disintegrant (External), and Aerosil 200 (External) are added to the mixture and bin blended. Thereafter, the obtained mixture is blended with Sodium Stearyl Fumarate (external excipient), sieved in a bin blender.
• the obtained final mixture is then compressed into a tablet weighing about 100 mg.
• the dissolution data of these examples at pH 6.8 are shown in the Table below.
• Dissolution medium 900 ml pH 6.8 Phosphate + 0.05% CTAB; Paddle at 75 rpm; HPLC method; rapid stir 45 to 60 min. Time (min) 10 20 30 45 60 % release of Example 5.1 36.3 73.3 83.4 90.3 93.8 compound (SSG) (2.8 kN) of formula (II)
• Example 5.2 27.9 65.0 84.3 92.0 94.0 PVP-XL
• Example 5.3 46.3 78.7 84.3 89.1 91.2 (Ac-di-sol) (2.5 kN)
• a most preferred disintegrant is sodium starch glycollate, which also gives a good friability level.
• the therapeutic agent in these examples is the compound of formula (II).
• the table below shows the formulation for Examples 6.1 to 6.4 having 25 mg of therapeutic agent—the 25 mg refers to the amount of the compound of formula (I). Tablets for examples 6.1 to 6.4 were made by the same process as described in example 2.
• Dissolution medium 900 ml pH 6.8 Phosphate + 0.05% CTAB (cetyltrimethyl ammonium bromide); Paddle at 75 rpm; HPLC method; rapid stir 45 to 60 min.
• CTAB cetyltrimethyl ammonium bromide
• Example 6.1 0% SSG 21.15 50.56 74.45 89.81 93.21 compound (3.0 kN) of Example 6.1: 0% SSG 32.66 77.01 91.90 93.40 94.28 formula (II) (7.9 kN)
• the dissolution profiles show a clear rank order in terms of level of disintegrant and the rate of dissolution up to 6% level. There was no significant difference in the release rates between 6% and 9%. Greater than 90% of the therapeutic agent is released from Examples with a disintegrant. Disintegrants usually decrease the compressibility of the formulation and higher levels will lead to decreased tablet hardness and/or friability problems. Thus, a fine balance must be struck between the amount of disintegrant and other properties of the formulation.
• the disintegrant is distributed equally between the internal and external components. E.g. 6% is distributed as 3% internal and 3% external components, respectively, and 2% is distributed as 1% internal and 1% external components, respectively
• the therapeutic agent in this example is the compound of formula (II).
• Tables below show the formulation for Example 7 having 2 mg of therapeutic agent; the 2 mg refers to the amount of the compound of formula (I).
• the therapeutic agent in these examples is the compound of formula (II).
• Table below shows the formulation for Examples 8.1 and 8.2 having 20 mg of therapeutic agent—the 20 mg refers to the amount of the compound of formula (I).
• a single center, randomized, open-label, single dose, parallel-group study is carried out to assess the relative bioavailability of the therapeutic agent following oral administration of a single dose of the compound of formula (II) as tablet (20 mg) formulations administered to healthy subjects under fasting or fed conditions (standard FDA breakfast).
• a total of 120 subjects are enrolled and equally distributed to 5 treatment arms (24 subjects/treatment arm, in a 1:1:1:1:1 ratio).
• PK pharmacokinetic
• Example 8.2 Example 1.B Example 8.1 Example 8.2 PK parameter fasted fasted tablet fed fed Tmax (hr) a N 24 24 24 23 22 Median 23.5 17.0 36.0 12.0 12.0 (min, max) (9.95, 144) (4.00, 120) (4.00, 144) (2.00, 119) (4.00, 48.0) Cmax (ng/mL) a N 24 24 24 23 22 Mean ⁇ 141 ⁇ 85.5 161 ⁇ 132 131 ⁇ 84.0 260 ⁇ 235 219 ⁇ 190 (% CV) (60.5) (81.7) (64.3) (90.4) (86.7) T(1 ⁇ 2) (hr) a,b N 23 24 23 22 22 Mean ⁇ 136 ⁇ 28.2 153 ⁇ 59.2 140 ⁇ 45.1 164 ⁇ 95.0
• Examples 8.1 and 8.2 are thus similar to Reference Example 1.B in terms of the rate and extent of absorption of the therapeutic agent.
• the invention thus provides a pharmaceutical composition of the compound of formula (I), or a pharmaceutically acceptable salt thereof, which exhibits one or more, e.g. 1, 2 or 3, of the following desirable characteristics;
• the formulations of the present invention are also achievable via a robust manufacturing process; which gives good flowability, compactability, and which minimizes sticking problems and capping of tabletting mixtures on the rotary press.
• the process and the formulations are amenable to scale-up, with a reproducible performance.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Inorganic Chemistry (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Child & Adolescent Psychology (AREA)
• Dermatology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Biochemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=44908106

Family Applications (5)

Family Applications After (4)

Country Status (29)

Cited By (8)

Families Citing this family (6)

Citations (2)

Family Cites Families (15)

• 2011
  • 2011-10-13 AR ARP110103797A patent/AR083417A1/es unknown
  • 2011-10-14 SG SG2013021944A patent/SG189078A1/en unknown
  • 2011-10-14 TR TR2019/02435T patent/TR201902435T4/tr unknown
  • 2011-10-14 PE PE2013000837A patent/PE20140375A1/es not_active Application Discontinuation
  • 2011-10-14 WO PCT/US2011/056275 patent/WO2012051488A1/en active Application Filing
  • 2011-10-14 EP EP11779278.8A patent/EP2627319B1/en active Active
  • 2011-10-14 KR KR1020137009333A patent/KR20130100311A/ko not_active Application Discontinuation
  • 2011-10-14 AU AU2011316003A patent/AU2011316003B2/en not_active Ceased
  • 2011-10-14 CA CA2813781A patent/CA2813781C/en active Active
  • 2011-10-14 SI SI201131677T patent/SI2627319T1/sl unknown
  • 2011-10-14 JP JP2013534025A patent/JP6060081B2/ja active Active
  • 2011-10-14 PT PT11779278T patent/PT2627319T/pt unknown
  • 2011-10-14 PL PL11779278T patent/PL2627319T3/pl unknown
  • 2011-10-14 MA MA35806A patent/MA34599B1/fr unknown
  • 2011-10-14 BR BR112013008757-9A patent/BR112013008757A2/pt not_active IP Right Cessation
  • 2011-10-14 DK DK11779278.8T patent/DK2627319T3/en active
  • 2011-10-14 RU RU2013121795/15A patent/RU2595866C2/ru active
  • 2011-10-14 HU HUE11779278A patent/HUE043524T2/hu unknown
  • 2011-10-14 MX MX2013004162A patent/MX2013004162A/es not_active Application Discontinuation
  • 2011-10-14 US US13/825,919 patent/US20130190354A1/en not_active Abandoned
  • 2011-10-14 CN CN201180049179.4A patent/CN103179957B/zh active Active
  • 2011-10-14 NZ NZ608558A patent/NZ608558A/en not_active IP Right Cessation
  • 2011-10-14 ES ES11779278T patent/ES2712064T3/es active Active
• 2013
  • 2013-03-20 ZA ZA2013/02108A patent/ZA201302108B/en unknown
  • 2013-03-21 IL IL225434A patent/IL225434A0/en unknown
  • 2013-04-11 GT GT201300096A patent/GT201300096A/es unknown
  • 2013-04-11 CO CO13094273A patent/CO6710915A2/es not_active Application Discontinuation
  • 2013-04-12 CL CL2013001001A patent/CL2013001001A1/es unknown
  • 2013-04-12 EC ECSP13012755 patent/ECSP13012755A/es unknown
• 2015
  • 2015-07-22 US US14/805,919 patent/US20150320687A1/en not_active Abandoned
• 2016
  • 2016-09-12 US US15/262,056 patent/US20160374947A1/en not_active Abandoned
• 2018
  • 2018-05-01 US US15/968,104 patent/US10646446B2/en active Active
• 2020
  • 2020-03-31 US US16/835,921 patent/US11304907B2/en active Active

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events